Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Spero Therapeutics (SPRO) Revenue (2016 - 2025)

Historic Revenue for Spero Therapeutics (SPRO) over the last 10 years, with Q3 2025 value amounting to $5.4 million.

  • Spero Therapeutics' Revenue fell 5959.61% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.5 million, marking a year-over-year decrease of 6190.97%. This contributed to the annual value of $48.0 million for FY2024, which is 5377.09% down from last year.
  • According to the latest figures from Q3 2025, Spero Therapeutics' Revenue is $5.4 million, which was down 5959.61% from $14.2 million recorded in Q2 2025.
  • In the past 5 years, Spero Therapeutics' Revenue ranged from a high of $73.5 million in Q4 2023 and a low of $2.0 million during Q2 2022
  • Over the past 5 years, Spero Therapeutics' median Revenue value was $5.9 million (recorded in 2025), while the average stood at $11.3 million.
  • In the last 5 years, Spero Therapeutics' Revenue skyrocketed by 116984.05% in 2023 and then plummeted by 7953.81% in 2024.
  • Spero Therapeutics' Revenue (Quarter) stood at $2.7 million in 2021, then surged by 371.28% to $12.9 million in 2022, then soared by 468.53% to $73.5 million in 2023, then tumbled by 79.54% to $15.0 million in 2024, then crashed by 63.83% to $5.4 million in 2025.
  • Its Revenue stands at $5.4 million for Q3 2025, versus $14.2 million for Q2 2025 and $5.9 million for Q1 2025.